{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:42:09Z","timestamp":1793299329810,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007212","name":"V\u00e4stra G\u00f6talandsregionen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The present study aimed to compare visual field progression in new-diagnosed exfoliation versus open-angle glaucoma patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study. The study included patients with new-diagnosed primary open-angle and exfoliation glaucoma. All patients were followed for 3 years with reliable visual fields. At least five reliable fields were needed for inclusion. Exfoliation and open-angle glaucoma were defined based on the European Glaucoma Society guidelines. Visual field evaluation was performed using the software threshold 24\u20132 of the Humphrey Field Analysis. Outcomes: Visual field progression. For visual field progression, three different strategies were used: mean deviation (MD), visual field index (VFI), and the guided progression analysis (GPA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 128 subjects, of the 54 in the open-angle and 74 in the exfoliation glaucoma group. The MD difference values were higher in the exfoliation (\u2212\u20093.17\u2009dB) than in the primary open-angle (\u2212\u20091.25\u2009dB) glaucoma group in the three-year follow-up period. The difference between groups was significant (t-test,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009&lt;\u20090.001). The difference in VFI was calculated for the 3 years follow-up period. The difference was higher in the exfoliation (\u2212\u20097.65%) than in the primary open (\u2212\u20091.90%) glaucoma group (t-test,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009&lt;\u20090.001). The GPA showed progression in 58% of cases in exfoliation, and 13% in primary open glaucoma group (Chi-square,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The present study found a more frequent and faster visual field progression in exfoliation than in primary open-angle glaucoma patients. New-diagnosed exfoliation glaucoma patients must be controlled and treated more strictly than primary open-angle glaucoma patients to avoid visual field deterioration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-020-01592-w","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T07:02:58Z","timestamp":1596610978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of visual field progression in new-diagnosed primary open-angle and exfoliation glaucoma patients in Sweden"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2556-7578","authenticated-orcid":false,"given":"Marcelo","family":"Ayala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"issue":"11","key":"1592_CR1","first-page":"844","volume":"82","author":"S Resnikoff","year":"2004","unstructured":"Resnikoff S, Pascolini D, Etya\u2019ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull WHO. 2004;82(11):844\u201351.","journal-title":"Bull WHO"},{"issue":"1","key":"1592_CR2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"MC Leske","year":"2003","unstructured":"Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48\u201356.","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"1592_CR3","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1600-0420.2007.00980.x","volume":"85","author":"S Astr\u00f6m","year":"2007","unstructured":"Astr\u00f6m S, Stenlund H, Lind\u00e9n C. Incidence and prevalence of pseudoexfoliations and open-angle glaucoma in northern Sweden: II. Results after 21 years of follow-up. Acta Ophthalmol Scand. 2007;85(8):832\u20137.","journal-title":"Acta Ophthalmol Scand"},{"issue":"5","key":"1592_CR4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.002","volume":"101","author":"European Glaucoma Society Terminology and Guidelines for Glaucoma","year":"2017","unstructured":"European Glaucoma Society Terminology and Guidelines for Glaucoma. Chapter 2: classification and terminologySupported by the EGS Foundation: part 1: foreword; introduction; glossary; chapter 2 classification and terminology. Br J Ophthalmol. 2017;101(5):73\u2013127.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"1592_CR5","first-page":"777","volume":"55","author":"K Zhou","year":"2019","unstructured":"Zhou K, Shang X, Wang XY, Wang XJ, Cheng HH, Hu HS, et al. Risk factors for visual field loss progression in patients with primary open-angle glaucoma in Wenzhou area. Zhonghua Yan Ke Za Zhi. 2019;55(10):777\u201384.","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"1592_CR6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ajo.2017.10.039","volume":"186","author":"L Mowatt","year":"2018","unstructured":"Mowatt L. Risk factors for rapid Glaucoma disease progression. Am J Ophthalmol. 2018;186:170\u20131.","journal-title":"Am J Ophthalmol"},{"key":"1592_CR7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ajo.2017.06.003","volume":"180","author":"TCW Chan","year":"2017","unstructured":"Chan TCW, Bala C, Siu A, Wan F, White A. Risk factors for rapid Glaucoma disease progression. Am J Ophthalmol. 2017;180:151\u20137.","journal-title":"Am J Ophthalmol"},{"key":"1592_CR8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/1874364101610010129","volume":"10","author":"AG Actis","year":"2016","unstructured":"Actis AG, Versino E, Brogliatti B, Rolle T. Risk factors for primary open angle Glaucoma (POAG) progression: a study ruled in Torino. Open Ophthalmol J. 2016;10:129\u201339.","journal-title":"Open Ophthalmol J"},{"issue":"4","key":"1592_CR9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0039-6257(00)00196-X","volume":"45","author":"R Ritch","year":"2001","unstructured":"Ritch R, Schlotzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001;45(4):265\u2013315.","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"1592_CR10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/ICU.0000000000000135","volume":"26","author":"S Dewundara","year":"2015","unstructured":"Dewundara S, Pasquale LR. Exfoliation syndrome: a disease with an environmental component. Curr Opin Ophthalmol. 2015;26(2):78\u201381.","journal-title":"Curr Opin Ophthalmol"},{"issue":"8 Suppl 1","key":"1592_CR11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/IJG.0000000000000119","volume":"23","author":"R Ritch","year":"2014","unstructured":"Ritch R. Ocular and systemic manifestations of exfoliation syndrome. J Glaucoma. 2014;23(8 Suppl 1):S1\u20138.","journal-title":"J Glaucoma"},{"issue":"6","key":"1592_CR12","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1111\/aos.12918","volume":"94","author":"LR Pasquale","year":"2016","unstructured":"Pasquale LR, Borras T, Fingert JH, Wiggs JL, Ritch R. Exfoliation syndrome: assembling the puzzle pieces. Acta Ophthalmol. 2016;94(6):e505\u201312.","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"1592_CR13","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/IJG.0000000000001391","volume":"28","author":"SU Baek","year":"2019","unstructured":"Baek SU, Kim YK, Park KH, Jeoung JW. Long-term follow-up on Glaucoma patients with initial single-Hemifield defect: progression patterns and associated factors. J Glaucoma. 2019;28(12):1041\u20137.","journal-title":"J Glaucoma"},{"issue":"7","key":"1592_CR14","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/bjophthalmol-2017-310635","volume":"102","author":"A Salonikiou","year":"2018","unstructured":"Salonikiou A, Founti P, Kilintzis V, Antoniadis A, Anastasopoulos E, Pappas T, et al. Tolerable rates of visual field progression in a population-based sample of patients with glaucoma. Br J Ophthalmol. 2018;102(7):916\u201321.","journal-title":"Br J Ophthalmol"},{"key":"1592_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1755-3768.2012.02415.x","volume":"251","author":"A Heijl","year":"2012","unstructured":"Heijl A, Alm A, Bengtsson B, Bergstrom A, Calissendorff B, Lindblom B, et al. The Glaucoma Guidelines of the Swedish Ophthalmological Society. Acta Ophthalmol Suppl. 2012;251:1\u201340.","journal-title":"Acta Ophthalmol Suppl"},{"issue":"2","key":"1592_CR16","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1167\/iovs.08-1789","volume":"50","author":"M Wall","year":"2009","unstructured":"Wall M, Woodward KR, Doyle CK, Artes PH. Repeatability of automated perimetry: a comparison between standard automated perimetry with stimulus size III and V, matrix, and motion perimetry. Invest Ophthalmol Vis Sci. 2009;50(2):974\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"1592_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/IJG.0000000000000710","volume":"26","author":"K Liebmann","year":"2017","unstructured":"Liebmann K, De Moraes CG, Liebmann JM. Measuring rates of visual field progression in linear versus nonlinear scales: implications for understanding the relationship between baseline damage and target rates of Glaucoma progression. J Glaucoma. 2017;26(8):721\u20135.","journal-title":"J Glaucoma"},{"issue":"1","key":"1592_CR18","doi-asserted-by":"publisher","first-page":"18113","DOI":"10.1038\/s41598-019-54653-6","volume":"9","author":"SI Berchuck","year":"2019","unstructured":"Berchuck SI, Mukherjee S, Medeiros FA. Estimating rates of progression and predicting future visual fields in Glaucoma using a deep Variational autoencoder. Sci Rep. 2019;9(1):18113.","journal-title":"Sci Rep"},{"issue":"12","key":"1592_CR19","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.ophtha.2009.06.042","volume":"116","author":"A Heijl","year":"2009","unstructured":"Heijl A, Bengtsson B, Hyman L, Leske MC. Natural history of open-angle glaucoma. Ophthalmology. 2009;116(12):2271\u20136.","journal-title":"Ophthalmology"},{"key":"1592_CR20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ajo.2019.02.015","volume":"202","author":"X Zhang","year":"2019","unstructured":"Zhang X, Parrish RK 2nd, Greenfield DS, Francis BA, Varma R, Schuman JS, et al. Predictive factors for the rate of visual field progression in the advanced imaging for Glaucoma study. Am J Ophthalmol. 2019;202:62\u201371.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1592_CR21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ogla.2018.11.004","volume":"2","author":"AT Nguyen","year":"2019","unstructured":"Nguyen AT, Greenfield DS, Bhakta AS, Lee J, Feuer WJ. Detecting Glaucoma progression using guided progression analysis with OCT and visual field assessment in eyes classified by international classification of disease severity codes. Ophthalmol Glaucoma. 2019;2(1):36\u201346.","journal-title":"Ophthalmol Glaucoma"},{"key":"1592_CR22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ajo.2019.06.019","volume":"207","author":"JH Kim","year":"2019","unstructured":"Kim JH, Rabiolo A, Morales E, Yu F, Afifi AA, Nouri-Mahdavi K, et al. Risk factors for fast visual field progression in Glaucoma. Am J Ophthalmol. 2019;207:268\u201378.","journal-title":"Am J Ophthalmol"},{"key":"1592_CR23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/1874364101509010116","volume":"9","author":"T Kocaturk","year":"2015","unstructured":"Kocaturk T, Bekmez S, Katranci M, Cakmak H, Dayanir V. Long term results of visual field progression analysis in open angle Glaucoma patients under treatment. Open Ophthalmol J. 2015;9:116\u201320.","journal-title":"Open Ophthalmol J"},{"issue":"3","key":"1592_CR24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1755-3768.2011.02260.x","volume":"91","author":"CG De Moraes","year":"2013","unstructured":"De Moraes CG, Liebmann JM, Liebmann CA, Susanna R Jr, Tello C, Ritch R. Visual field progression outcomes in glaucoma subtypes. Acta Ophthalmol. 2013;91(3):288\u201393.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"1592_CR25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/ahg.12128","volume":"79","author":"P Founti","year":"2015","unstructured":"Founti P, Haidich AB, Chatzikyriakidou A, Salonikiou A, Anastasopoulos E, Pappas T, et al. Ethnicity-based differences in the association of LOXL1 polymorphisms with Pseudoexfoliation\/Pseudoexfoliative Glaucoma: a meta-analysis. Ann Hum Genet. 2015;79(6):431\u201350.","journal-title":"Ann Hum Genet"},{"key":"1592_CR26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.pbr.2015.04.011","volume":"221","author":"JR Vianna","year":"2015","unstructured":"Vianna JR, Chauhan BC. How to detect progression in glaucoma. Prog Brain Res. 2015;221:135\u201358.","journal-title":"Prog Brain Res"},{"issue":"9","key":"1592_CR27","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/bjophthalmol-2012-301820","volume":"96","author":"DC Musch","year":"2012","unstructured":"Musch DC, Shimizu T, Niziol LM, Gillespie BW, Cashwell LF, Lichter PR. Clinical characteristics of newly diagnosed primary, pigmentary and pseudoexfoliative open-angle glaucoma in the collaborative initial Glaucoma treatment study. Br J Ophthalmol. 2012;96(9):1180\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"1592_CR28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00061198-200212000-00012","volume":"11","author":"PM Puska","year":"2002","unstructured":"Puska PM. Unilateral exfoliation syndrome: conversion to bilateral exfoliation and to glaucoma: a prospective 10-year follow-up study. J Glaucoma. 2002;11(6):517\u201324.","journal-title":"J Glaucoma"},{"issue":"7","key":"1592_CR29","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/archopht.119.7.1023","volume":"119","author":"T Hammer","year":"2001","unstructured":"Hammer T, Schlotzer-Schrehardt U, Naumann GO. Unilateral or asymmetric pseudoexfoliation syndrome? An ultrastructural study. Arch Ophthalmol. 2001;119(7):1023\u201331.","journal-title":"Arch Ophthalmol"},{"key":"1592_CR30","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2147\/OPTH.S166958","volume":"12","author":"M Ayala","year":"2018","unstructured":"Ayala M, Cuklev F. Indistinguishable gene expression between healthy eyes and eyes with unilateral exfoliative glaucoma. Clin Ophthalmol. 2018;12:1155\u201362.","journal-title":"Clin Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01592-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-020-01592-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01592-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T19:41:02Z","timestamp":1628106062000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01592-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1592"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01592-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-34864\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-34864\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-34864\/v1","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,5]]},"assertion":[{"value":"11 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Swedish Ethical Authority, Uppsala, DN 2020\u201303175. Written consent from the patients was not necessary for this non-interventional retrospective chart-review study. No administrative permissions were required to access the raw data from the database. Patient data were de-identified prior to data collection.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"322"}}